3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Endometrial Neoplasms
10
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer (LARC)
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Mouth Neoplasms
1
Interventions
fludarabine
2
Paclitaxel
2
Nivolumab
2
Bevacizumab
2
rucaparib
1
liposomal doxorubicin
1
dostarlimab
1
Sunitinib
1
Stem Cell Transplantation
1
Sirolimus
1
Radiotherapy
1
Melphalan
1
Ipilimumab
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Dexamethasone
1
Celecoxib
1
Carboplatin
1
Capecitabine
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma, Clear Cell
×
dostarlimab
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled